A 66-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma
Amrita Krishnan, MD, discusses the evolving treatment landscape for early relapsed/refractory multiple myeloma, focusing on CAR T-cell therapy selection, sequencing, and management. Key areas covered include KarMMa-3 trial data for ide-cel, real-world evidence, toxicity management, community practice strategies, and emerging therapeutic approaches. Emphasis is placed on optimal patient care from selection through long-term monitoring, with consideration of novel combinations and future directions.
EP. 1: A 70-Year-Old Man with Early Relapsed/Refractory Multiple Myeloma
January 20th 2025The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
Watch
EP. 2: Evolving Paradigms, CAR T, and Treatment Selection in Early-Stage R/R MM
January 20th 2025The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel [ide-cel, cilta-cel]) and novel drug combinations. Treatment selection now considers prior therapies, patient characteristics, and response duration. For third-line chimeric antigen receptor (CAR) T after no prior CAR T use, cilta-cel shows favorable efficacy data with deeper, more durable responses than ide-cel, though both are viable options.
Watch
